Format

Send to

Choose Destination
Curr Opin Immunol. 2016 Jun;40:51-61. doi: 10.1016/j.coi.2016.03.001. Epub 2016 Mar 23.

Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.

Author information

1
Humabs BioMed SA, 6500 Bellinzona, Switzerland. Electronic address: davide.corti@humabs.ch.
2
Merrimack Pharmaceuticals, Inc., One Kendall Square, Suite B7201, Cambridge, MA 02139, USA. Electronic address: jkearns@merrimack.com.

Abstract

Monoclonal antibodies (mAbs) have revolutionized the diagnosis and treatment of many human diseases and the application of combinations of mAbs has demonstrated improved therapeutic activity in both preclinical and clinical testing. Combinations of antibodies have several advantages such as the capacities to target multiple and mutating antigens in complex pathogens and to engage varied epitopes on multiple disease-related antigens (e.g. receptors) to overcome heterogeneity and plasticity. Oligoclonal antibodies are an emerging therapeutic format in which a novel antibody combination is developed as a single drug product. Here, we will provide historical context on the use of oligoclonal antibodies in oncology and infectious diseases and will highlight practical considerations related to their preclinical and clinical development programs.

PMID:
26995095
DOI:
10.1016/j.coi.2016.03.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center